Evaluation of the relationship between toxicity of cyclin-dependent kinase 4/6 inhibitors and body surface area

被引:0
|
作者
Disli, Safak Yildirim [1 ]
Fidan, Evren [2 ]
机构
[1] Kayseri City Hosp, Dept Med Oncol, Kayseri, Turkiye
[2] Karadeniz Tech Univ, Dept Med Oncol, Trabzon, Turkiye
来源
关键词
Breast cancer; Drug toxicity; Body measures; Toxicity; BREAST-CANCER; MASS INDEX;
D O I
10.1590/1806-9282.20230680
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE: This study aimed to evaluate the relationship between the toxicity of cyclin-dependent kinase 4/6 inhibitors and body mass index and body surface area.METHODS: A total of 83 patients were included in the study. Patients were divided into 4 groups as 18-24.9, 25-29.9, 30-39.9, and >40 kg/m(2) according to body mass index and into two groups as below and above 1.77 according to body surface area. The relationship between body mass index and body surface area and side effects was evaluated.RESULTS: No statistically significant difference was found between body mass index groups and side effects. Grade 3 neutropenia was more common in patients on palbociclib with a body surface area <= 1.77. In our study, it was revealed that less hematological side effects can be encountered when body surface area is taken into account.
引用
收藏
页数:4
相关论文
共 50 条
  • [1] Mechanisms of resistance to cyclin-dependent kinase 4/6 inhibitors
    Georgia Gomatou
    Ioannis Trontzas
    Stephanie Ioannou
    Maria Drizou
    Nikolaos Syrigos
    Elias Kotteas
    Molecular Biology Reports, 2021, 48 : 915 - 925
  • [2] Mechanisms of resistance to cyclin-dependent kinase 4/6 inhibitors
    Gomatou, Georgia
    Trontzas, Ioannis
    Ioannou, Stephanie
    Drizou, Maria
    Syrigos, Nikolaos
    Kotteas, Elias
    MOLECULAR BIOLOGY REPORTS, 2021, 48 (01) : 915 - 925
  • [3] Cyclin-Dependent Kinase 4/6 Inhibitors Against Breast Cancer
    Hassan, Mohammed Al-Kassim
    Ates-Alagoz, Zeynep
    MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2023, 23 (04) : 412 - 428
  • [4] Cyclin-dependent kinase 4/6 inhibitors in breast cancer therapy
    Migliaccio, Ilenia
    Di Leo, Angelo
    Malorni, Luca
    CURRENT OPINION IN ONCOLOGY, 2014, 26 (06) : 568 - 575
  • [5] Cyclin-dependent kinase inhibitors
    Westwell, A
    DRUG DISCOVERY TODAY, 2001, 6 (09) : 491 - 491
  • [6] Cyclin-dependent kinase inhibitors
    Dai, Y
    Grant, S
    CURRENT OPINION IN PHARMACOLOGY, 2003, 3 (04) : 362 - 370
  • [7] Management of Adverse Events Due to Cyclin-Dependent Kinase 4/6 Inhibitors
    Ettl, Johannes
    BREAST CARE, 2019, 14 (02) : 86 - 92
  • [8] Multiple Roles of Cyclin-Dependent Kinase 4/6 Inhibitors in Cancer Therapy
    Roberts, Patrick J.
    Bisi, John E.
    Strum, Jay C.
    Combest, Austin J.
    Darr, David B.
    Usary, Jerry E.
    Zamboni, William C.
    Wong, Kwok-Kin
    Perou, Charles M.
    Sharpless, Norman E.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2012, 104 (06): : 476 - 487
  • [9] Cyclin-Dependent Kinase 4/6 Inhibitors: Is a Noncanonical Substrate the Key Target?
    Frank, David A.
    CANCER RESEARCH, 2022, 82 (07) : 1170 - 1171
  • [10] Cdk pathway: Cyclin-dependent kinases and cyclin-dependent kinase inhibitors
    Gitig, DM
    Koff, A
    MOLECULAR BIOTECHNOLOGY, 2001, 19 (02) : 179 - 188